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The workshop "Characterizing the Effects of Endocrine Disruptors on Human Health at
Environmental Exposure Levels" was held to provide a forum for discussions and
recommendations of methods and data needed to improve risk assessments of endocrine
disruptors. This article was produced by a working group charged with determining the basic
mechanistic information that should be considered when designing models to quantitatively assess
potential risks of environmental endocrine disruptors in adults. To reach this goal, we initially
identified a set of potential organ system toxicities in males and females on the basis of known
and/or suspected effects of endocrine disruptors on estrogen, androgen, and thryoid hormone
systems. We used this integrated, systems-level approach because endocrine disruptors have the
potential to exert toxicities at many levels and by many molecular mechanisms. Because a detailed
analysis of all these untoward effects was beyond the scope of this workshop, we selected the
specific end point of testicular function for a more detailed analysis. The goal was to identify the
information required to develop a quantitative model(s) of the effects of endocrine disruptors on this
system while focusing on spermatogenesis, sperm characteristics, and testicular steroidogenesis
as specific markers. Testicular function was selected because it is a prototypical integrated end
point that can be affected adversely by individual endocrine disruptors or chemical mixtures acting
at one specific site or at multiple sites. Our specific objective was to gather the information needed
to develop models in the adult organism containing functional homeostatic mechanisms, and for
this reason we did not consider possible developmental toxicities. Homeostatic mechanisms have
the potential to ameliorate or lessen the effects of endocrine disruptors, but these pathways are
also potential target sites for the actions of these chemicals. Key words: androgen, estrogens,
endocrine disruptors, homeostasis, spermatogenesis, testicular steroidogenesis, thyroid hormones.
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The endocrine system ofadult animals is
equipped with a set ofmechanisms that regu-
late circulating levels ofendogenous hor-
mones. For example, a series offeedback
loops involving the hypothalamus, pituitary,
and the gonads, adrenals, and thyroid gland
regulates the synthesis ofsex steroids, gluco-
corticoids, and thyroid hormones, respec-
tively. At the same time, elimination ofthese
hormones via biotransformation is catalyzed
by enzymes in the liver and other sites that
are inducible by hormones themselves as well
as other agents (1,2). Thus, the adult mam-
malian organism has several homeostatic
mechanisms that maintain the levels of
endogenous estrogens, androgens, and
thyroid hormoneswithin certain ranges.
These same homeostatic mechanisms also
can dampen or moderate the effects of
endocrine disruptors that affect estrogenic,
androgenic, or thyroid hormone systems. In
addition it is well established that many acute
effects ofabnormally high or low levels of
endogenous hormones are reversible, e.g.,
normal menstrual cycles resume when
women discontinue using contraceptives (2),
and it is reasonable to expect that the same
might be true ofacute effects ofendocrine
disruptors. This is in contrast to the develop-
ing organism in which feedback mechanisms
controlling hormone synthesis and elimina-
tion mechanisms controlling hormone degra-
dation may not be fully functional and in
which early developmental exposures may
lead to irreversible changes. Hence, it seems
appropriate to discuss potential effects of
endocrine disruptors in the adult separately
from those in the developing organism, and
this article focuses on theformer.
Aworkshop oncharacterizing the effects of
endocrine disruptors on human health at envi-
ronmental exposure levels was held to provide
a forum for discussions and recommendations
ofmethods and data needed to improve risk
assessments ofendocrine disruptors. The
authors of this article were members of a
working group that addressed homeostasis and
endocrine function in adults and how pertur-
bations ofendocrine homeostasis may lead to
disease. The charge to this working group was
to determine the basic mechanistic informa-
tion that should be considered when design-
ing models to quantitatively assess the risks of
endocrine disruptors present at environmen-
tally relevant levels. The specific focus was on
endocrine disruptors that affect estrogen,
androgen, and thyroid hormone systems, but
in the broadest conceptual sense. To some
extent, the required mechanistic information
depends upon the specific end point one
wishes to model, and during a 2-day meeting
it was dearly impossible to develop a compre-
hensive list ofinformation required to analyze
all possible adverse effects ofevery potential
endocrine disruptor. Therefore, our approach
was to consider a variety ofpotential unto-
ward effects on the basis ofour collective
knowledge ofendocrine mechanisms, to select
one we feltwas amenable to development ofa
risk assessment model, and to delineate the
information necessary to construct a model.
This would provide a starting point for analy-
sis ofone end point, but more important
would illustrate the general considerations
that basic endocrinologists would incorporate
into a model ofendocrine disruptor actions.
Many ofthese considerations would likely
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pertain to the effects ofendocrine disruptors
on other systems and thus are likely to have
somegeneralizedapplicability.
Once a model system was selected, the
goal was to answer questions originally posed
by the organizing committee, which the
working group also thought were important
to consider. These areas follows:
* Are there adequate/relevant animal
models for evaluating potential human
effects oflow-dose exposure to endocrine
disruptors?
* What should be included in baseline
models to adequately describe quantita-
tive relationships among the processes
maintaininghomeostasis?
* How do perturbations in this balance lead
to disease, e.g., impaired reproductive
function, cancer?
* Howcan thesechanges be quantified?
* By what mechanisms do endocrine dis-
ruptors perturb endocrine homeostasis
and function and alter risks from normal
levels ofendogenous hormones?
* How do differences in lifestyle factors
(e.g., diet, nutritional status, physical
activity) affect sensitivity to endocrine
disruptors?
* How does the age ofthe endocrine system
altersusceptibility toendocrinedisruptors?
Overview ofEndocrine
DisruptorAction
The biologic actions ofendocrine disruptors
are produced by the same general mecha-
nisms as those ofother chemicals including
hormones, drugs, or other toxicants. The
action ofall chemicals on the body may be
divided by dichotomy into two major steps.
The first is the series ofinteractions between
the portal ofentry ofthe endocrine disruptor
and its concentration at tissue sites. These
interactions involve absorption, distribution
(e.g., binding to plasma proteins, sequestra-
tion in tissue sites), and elimination ofthe
endocrine disruptor. The second set ofinter-
actions dictates the magnitude ofthe effect
the endocrine disruptor produces at various
tissue sites. These interactions involve the
entire series ofcellular events between the ini-
tial interaction ofthe endocrine disruptor at
receptors (or nonreceptor sites) and the ulti-
mate biologic response ofthe target cell. This
simplified schema is illustrated in Figure 1.
Pharmaokinctic Isues
The conceptual framework required to
describe the relationships between the amount
ofan endocrine disruptor that enters the body
ataportalofentryand its concentration at tis-
sue sites is already available. However, several
specific research needs must be met ifwe are
actually to obtain reliable quantitative mea-
sures ofthese parameters. These include the
following: a) The analytic capability must be
available to measure amounts ofendocrine
disruptors in the body after exposure to envi-
ronmentally relevant levels. In most cases the
chemical or immunologic methods and
reagents used to make these measurements
are unavailable. b) In the same vein, there is
often no reliable and affordable source from
which investigators may obtain high-purity
endocrine disruptors. Compounds ofverified
purity are essential to unequivocally assign
biologic actions to parent compounds (rather
than impurities) and to provide standards for
analysis ofcompound levels in biologic sam-
ples and the environment. c) Another impor-
tant need is for appropriate radioactively
labeled endocrine disruptors to accurately
determine pharmacokinetic parameters,
levels ofspecific metabolites in bodily fluids
and tissues, and receptor-binding properties.
This may be especially critical for identifying
products formed by biotransformation of
endocrine disruptors that may have greater,
lesser, or qualitatively different biologic activ-
ity than the parent compound. Ifthese needs
can be met, determining the important
pharmacokinetic parameters foranyendocrine
disruptor becomes technically feasible. In the
absence ofexperimental data atlowexposures,
a physiologically realistic model that repro-
duces effects measured at higher doses can
be used to extrapolate to environmentally
relevant levels.
EndocrineDisruptorActions
atTargetOrgan Sites
The conceptually more challenging issue is to
develop quantitative models based on biologic
mechanisms that can be used to predict
adverse effects ofendocrine disruptors at vari-
ous tissue sites after low-dose exposures. This
requires a knowledge ofthe concentration of
endocrine disruptor at the target site, the
nature ofthe effect(s) produced in the tissue, a
determination ofwhat degree ofchange con-
stitutes an adverse effect, the basic mecha-
nism(s) involved, and the nature of the
dose-response relationship for the endocrine
disruptor. Ifthe endocrine disruptor alters the
levels ofendogenous hormones or any oftheir
biologically relevant metabolites, then the
dose-response relationships for these mole-
cules is also required. Similarly, ifthe toxicant
alters the expression ofproteins regulated by
the hormone receptor, measurement ofthose
responses is required.
Given this perspective, we initially
developed a list oftarget organ sites in both
Endocrine disruptor
in environment
Absorption via
portal(s) of entry
* Effect
Metabolite
Plasma space
Effect
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-Metabolism
-Excretion
release
Accumulation in depots
Figure 1. Overview of endocrine disruptor action. An endocrine disruptor (ED) present in the environment (upper left
corner) enters the body at one or more portals of entry and is absorbed into the plasma compartment, where it may
exist free or bound to plasma proteins. The ED may be eliminated (bottom left) by metabolism to an inactive com-
pound and/or excretion via the urine or other routes. The ED distributes to tissue compartments (right panels). At site
1 the endocrine disruptor produces an effect following binding to a hormone receptor (R), and at site 3 the ED pro-
duces an effect via a nonreceptor mechanism. At site 2 an ED with little or no intrinsic activity may undergo bio-
activation to yield a metabolite(s) that may disrupt the endocrine system via receptor (site 1) or nonreceptor (site 3)
mechanisms. The ED may also accumulate in depot sites such as adipose tissue (site 4) and undergo slow release
over prolonged periods oftime.
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the male and female at which potential
endocrine disruptors affecting estrogen,
androgen, or thyroid hormone systems
should be considered. This listing does not
imply that such actions are established or
even likely. Rather, the objective is to develop
a list ofsites and effects that a knowledgeable
endocrinologist would examine to determine
ifa chemical were acting as an endocrine dis-
ruptor. A listing of such sites is given in
Tables 1 and 2 for the female and male,
respectively. In addition, potential adverse
effects ofendocrine disruptors at each site are
also given. In many cases, effects at multiple
sites and involving multiple mechanisms are
listed as having the potential to produce the
same effect. For example, a hormonelike
effect could be produced directly by an
endocrine disruptor with agonist activity
occupying a receptor site in the tissue in ques-
tion. Alternatively, the same action at a tissue
site could be produced by an endocrine
disruptor acting on the hypothalamic-
pituitary-gonadal axis to increase endogenous
hormone production, or by actions at the
liver to decrease elimination ofendogenous
hormones, etc.
Because ofthe large number ofpotential
effects, each was further ranked as being of
high, medium, or low concern. This ranking
of effects is admittedly subjective, but it
represents a consensus (unanimity in almost
Table 1. Potential sites ofendocrine disruptor effects in the adultfemale and priority level of concern.
Priority concern of effect
Site High Medium Low
Uterus Infertility Menstrual bleeding Infection
Tumors Endometriosis
Oviduct
Vagina
Mammary gland
Ovary
Hypothalamus and
pituitary
Brain
Thyroid
Bone
Cardiovascular
system
Cancer
Lactation
Ovulation
Oocyte number
Cancer
Steroidogenesis
Altered cyclicity
Ovulatoryfailure
Reproductive senescence
Tumors
Hormone secretion
Stroke
Cancer
Infertility
Vaginitis
Fibrocystic disease
Luteal phase defects
Cysts
Onset of puberty
Sexual behavior
Alzheimer's disease
Dementia
Depression
Hormone secretion
Goiter
C-cell tumors
Osteoporosis
Hypertension
Coronary artery
disease
Venous thromboembolic
disease
Gastrointestinal tract
Adrenal
Adipose tissue Accumulation of
endocrine disruptors
Immune system
Hormone metabolism
Tumors
Colon cancer
Ca2+absorption
Bioactivation (of
endocrine disruptors)
Steroidogenesis
Metabolism of endocrine
disruptors and hormones
Autoimmune disease
Immunocompetence
Serum-binding protein
synthesis
Biliaryfunction
Hormone clearance
Ion transportand
fluid secretion
Mobility
Lipoprotein synthesis
Clotting factor
synthesis
Acne
Hirsutism
Hormone metabolism
Baldness
Atrophy
Incontinence
all cases) ofthe working group on the basis of
the following criteria: a) the likelihood that
the effect would have a substantive impact on
reproduction and hence survival of the
species; b) the likelihood that the effectwould
be potentially life threatening to an affected
individual; c) the impact ofthe effect on the
quality oflife of an individual; and d) the
estimated likelihood that environmentally rel-
evant levels ofendocrine disruptors are suffi-
cient to actually produce the effect. These
criteria were not weighted quantitatively in
the ranking process but were considered in
toto by members of the working group in
reachingtheir individual levels ofconcern.
To further focus potential future studies,
theworking group selected a smaller subset of
potential effects from Tables 1 and 2. This
selection was performed on the basis ofper-
ceived importance for human health and the
potential likelihood that quantitative models
ofthe effect could be developed that would
be useful for predicting low-dose effects in
the human population. In most cases, the
effect selected is actually an aggregate
response expected to result from the action of
an endocrine disruptor at multiple sites. The
effects selected were testicular function,
endometrial cancer, the female hypo-
thalamic-pituitary-gonadal axis up to and
including successful implantation, reproduc-
tive senescence in the female, mammary
cancer, and adverse effects on the cardiovas-
cular system and bone. Testicular function
was subsequently chosen as the effect to con-
sider as a prototype for modeling studies and
is discussed at length in the last section ofthis
article. A briefrationale for considering each
of the other six effects follows and is pre-
sented as a possible stimulus for modeling
studies focusingon these end points.
Endometrial Cancer
Endometrial cancer is a major human disease
that affects tens of thousands ofwomen in
the United States each year. Epidemiologic
studies have firmly established that exposure
to exogenous estrogens increases the risk of
endometrial cancer in postmenopausal
women receiving hormone replacement ther-
apy (3), and much evidence suggests that
total lifetime exposure to endogenous estro-
gens is a major risk factor for this disease and
other human cancers (4). The rodent uterus
has been one ofthe most extensively studied
in vivo models ofendocrine-disruptor action,
and there are several very plausible molecular
mechanisms by which exposure to environ-
mental estrogens would be expected to alter
the incidence ofthis disease. In addition, the
endometrium is one of the most sensitive
estrogen-responsive tissues, and endometrial
biopsies are potentially available for the study
ofhuman exposures and theirsequelae.
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Table2. Potential sites ofendocrine disruptor effects in the adult maleand priority level ofconcern.
Priorityconcern ofeffect
Site High Medium Low
Testis Spermatogenesis Varicocele
Tumors
Peptide hormone
synthesis
Steroidogenesis
Sperm maturation
Sperm transport
Tumors
Benign prostatic hyperplasia
Fluid composition
Fluid composition
Tumors
Hormone secretion
Cancer
Erectile dysfunction
Cancer
Gynecomastia
Puberty onset
Sexual behavior
Stroke
Hormone secretion
Goiter
Obstruction
Infection
Prostatitis(various)
Obstruction
Cysts
Ejaculatory dysfunction
Reproductive senescence
Aggression
C-cell tumors
Osteoporosis
Bone maturation
Coronaryartery disease
Hypertension
Venousthromboembolism
Gastrointestinal tract Motility
Hormone clearance
Hormone metabolism
Endocrine disruptor
accumulation
Steroidogenesis
Hypertrophy
Atrophy
Acne
Baldness
Hormone metabolism
Hormone distribution
Androgen-regulated
proteins
Antibody secretion
into genital tract
Thefemale hypothalamic-pituitary-
gonadaxi to and inc ngsweid
implantation. There is a wealth ofinforma-
tion describing the physiologic interplay of
the brain-pituitary-ovarian axis, the regula-
tion offollicular development, ovulation, and
implantation in both the rat and human. For
many ofthese processes, homologous mecha-
nisms have been identified for the rodent and
human. Furthermore, this endocrine axis has
been the focus of numerous toxicologic
studies identifying both the target tissue(s)
and cellular mechanisms involved in adverse
changes in the female's reproductive capacity.
In rodent models, environmental agents tar-
get the central nervous system and disrupt the
hypothalamic control of anterior pituitary
leutinizing hormones (LH) and prolactin
secretion (both xenoestrogens and non-
estrogenic neuroactive compounds) (5-7),
the pituitary itself(i.e., metals, xenoestrogens)
(8), the ovary (e.g., loss offollides, disruption
ofovulation, and modified corpus luteum
function), and ova transport and implanta-
tion (e.g., agents that disrupt prolactin and
progesterone availability) (9,10). In many
cases dose-response data on the toxicant
are available.
Reproductiw Senesence in theFemale
Female reproductive senescence (menopause)
results from ovarian depletion ofoocytes (pri-
mordial follides) that are available to develop
for ovulation. Environmental chemicals that
extensively destroy primordial follicles can
lead to premature menopause because the
pool ofprimordial follides is nonregenerating
(11). Menopause is associated with a variety
ofhealth problems, including osteoporosis,
cardiovascular disease, arthritis, urinary tract
infections, depression, and an increased risk
of ovarian cancer. Therefore, as a woman
ages, her overall health is significantly affected
by the onset ofmenopause, which can be fur-
ther impacted by environmental factors.
Several classes ofenvironmental chemicals,
chemotherapeutic agents, occupational epox-
ides, and polycyclic aromatic hydrocarbons
(e.g., compounds contained in cigarette
smoke) destroy primordial follicles in labora-
tory animals (11). Epidemiologic evidence
indicates that these agents also shorten the
reproductive life span ofwomen (12). For
example, women smokers are known to enter
menopause 2-6 years earlier than nonsmok-
ers. Therefore, chemicals that cause pre-
mature ovarian failure can be classified as
indirect endocrine disruptors because they
destroy the source of steroid hormones,
which interferes with their target organs and
disrupts the balanced pattern of neuro-
endocrine hormone feedbacks.
Because the adverse effects oflow-dose
exposure to reproductive toxicants may be
more prominent after chronic exposure,
effects such as reproductive senescence in
the female (i.e., menopause in humans,
reproductive life span in rodents and
humans) that occur gradually over time may
be especially important to evaluate. As noted
above, there are a number ofstudies suggest-
ing that environmental agents may acceler-
ate the loss ofovarian follicles in humans.
One concern for this parameter is the lack of
an appropriate animal model. However,
identifying an accelerated loss ofovarian fol-
licles in response to low-dose exposure in the
rat could provide useful information for
identifying potential human toxicants.
Reproductive aging in the female rodent has
been studied extensively and as the final dis-
ruption of reproductive capacity in the
female represents the cumulative effects of
events occurring throughout the animal's life
span, this measure could be particularly
sensitive to low-dose exposures.
MammaryCancer
Breast cancer is the most common endocrine-
related malignancy among women, with an
estimated 180,000 new cases diagnosed each
year in the United States alone. Ultimately,
1 of 10 women will develop breast cancer
duringher lifetime. Development ofthe nor-
mal breast, carcinogenesis, and the pro-
gression ofbreast cancer are regulated by
hormones and growth factors, among which
the effects ofestrogens are especially promi-
nent and best understood at the molecular
level. Studies using both mammary tumors in
rodents and human breast cancer cells in
culture have established that estrogens affect
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mammary epithelial cell proliferation and
differentiation, induce growth factor produc-
tion, and alter the expression ofproteolytic
enzymes and cell adhesive molecules (13,14).
Breast cancer cells express a diversity ofnor-
mal and mutated estrogen receptor tran-
scripts which, if translated into functional
proteins, could produce receptors with differ-
ent affinities for natural and synthetic estro-
gens (15). In addition, selected estrogen
metabolites can lead to the formation of
covalent DNA adducts and trigger damage
(16). The possibility that prolonged expo-
sure to endocrine disruptors has an adverse
effect on the development of breast cancer
requires careful consideration and analysis.
Adverse cardiovascular and skeletal
actions. Estrogens protect against athero-
sclerosis and myocardial infarcts in pre-
menopausal women. The cardiovascular
protection ofestrogens is mediated indirectly
by effects on lipoprotein metabolism, and
more recent studies have indicated these hor-
mones may have direct protective actions on
vascular smooth muscle and endothelium
(17). Osteoporosis, which primarily affects
postmenopausal women, represents a progres-
sive bone loss, reflecting a shift in the balance
between cells responsible for bone formation
and resorption. In studies using rodents,
estrogens inhibit bone loss at relatively low
concentrations (18). Interestingly, both vas-
cular and bone cells have recently been
reported to express the newly discovered
estrogen receptor P and to have a higher
binding affinity for several environmental
estrogens (e.g., genistein, coumestrol) than
the classical estrogen receptor a (19-21).
Cardiovascular disease is the leading cause of
death in women and fractures in elderly
women are a major cause ofmorbidity and
mortality. It thus seems particularly impor-
tant to elucidate the potential effects of
endocrine disruptors, both detrimental and
beneficial, on these conditions.
Conceptual Approach to
Develop a Model to Analyze
Low-Dose Effects of Endocrine
Disruptors on Testicular
Function
The general process we selected as a
prototype for modeling purposes is testicular
function, and within that overall process
there are three specific functional end points
we chose to consider, spermatogenesis,
sperm characteristics, and steroidogenesis.
Testicular function was selected for several
major reasons: a) these are significant bio-
logic end points for the health and quality of
life ofthe individual as well as the survival of
the species, b) it should be possible in some
cases to obtain human as well as animal data
that can be used to corroborate the models
one develops, and c) collectively these end
points provide an integrated readout of a
coordinated biologic system that is subject
to endocrine disruption by many toxicants
acting at a number ofsites and by a variety
of mechanisms. This last point might be
particularly important for several reasons
when considering endocrine disruptors.
First, a single endocrine disruptor might
affect the male reproductive system at multi-
ple sites, and hence an effect at one ofthe
cumulative end points noted above might
occur at a lower dose than an effect at a sin-
gle target site studied individually. For
example, a relatively small fractional inhibi-
tion ofseveral steps in a pathway may lead
to a more dramatic quantitative change in
the overall end point of the pathway.
Second, an end point such as testicular func-
tion may be used to study the effects ofmix-
tures of endocrine disruptors and other
toxicants that may act at different sites and
by different mechanisms, all ofwhich would
affect net testicular function.
AreThereAdequate/RelevantAnimal
ModelsforEvalingPotental
Human Effects?
One ofthe attractive features ofdeveloping
a model to analyze the effects of endocrine
disruptors on testicular function is that a
number of good animal models are avail-
able. Baboons and Old World monkeys are
particularly good models for the study of
spermatogenesis and sperm characteristics.
Certain aspects of these processes can also
be studied in rodent models that would be
relevant to humans, and rodent models are
particularly useful for certain laboratory-
based experimental studies. In addition,
domestic farm animals are also available,
and in many cases extensive data on these
parameters are available from historical
breeding records. The enzymatic pathways
involved in testicular steroidogenesis are
essentially identical in humans and most
other mammals, the structure and regula-
tion of the enzymes from different species
are generally quite similar, and there is a
large amount ofavailable literature on these
pathways, hormone levels, etc., in humans
and animal species. As previously noted,
another important consideration is that
human data can be obtained in many cases
to validate animal-based models. It should
also be noted that the sensitivity ofdifferent
species to an endocrine disruptor may vary
dramatically. The availability of a number
of animal models provides the opportunity
to study those with sensitivities similar to
humans or at least to study sensitive animal
species in cases for which human sensitivity
is not yet established.
WhatShouldBeIndudedin Baseline
Models toAdequatelyDescribe
QuantitativeRelationships amongthe
Processes MaintainingHomeostasis?
The major information included in models
falls into one ofseveral categories. One major
area is spermatogenesis and daily sperm pro-
duction rates are a major parameter to be
incorporated. In conjunction with a measure
ofthe quantity of sperm produced, standard
measures of sperm characteristics must also
be included, e.g., sperm motility and mor-
phology, sperm penetration assay, cervical
mucus penetration.
Substantial information on hormone levels
should also be included in models oftesticular
function. Serum levels of the peptide hor-
mones LH, follicle-stimulating hormone, pro-
lactin, and inhibin should be provided, as well
as free and protein-bound levels of numerous
steroids (testosterone, dihydrotestosterone,
androstenedione, estradiol, 17-hydroxyproges-
terone). The actual testicular levels ofsteroids
should also be measured, as endocrine disrup-
tors could conceivably affect the two pools of
steroid hormones differentially. Sample collec-
tion should be performed at multiple times to
account forpulsatile hormone secretion, circa-
dian rhythms, and seasonal variations, and
these should be incorporated into models.
Also, the rates ofproduction ofthese hor-
mones under various conditions and their
rates ofdegradation are required for a baseline
model as well as their binding affinities for
plasma and cellular proteins.
In addition to these biochemical meas-
ures, morphometric studies should be per-
formed to measure the number of cells
present for all major cell types in the testes,
to assess the number and nature ofcell-cell
associations; and mitosis and meiosis (the
number and nature ofcells at various stages
ofspermatogenesis).
Although it might be difficult to incorpo-
rate information on fertility into quantitative
models ofrisk assessment, it would be impor-
tant to obtain information on this parameter
to see ifchanges and trends in this parameter
appear consistent with the more readily quan-
tifiable measures above. Data on male fertility
in both humans and domestic animals should
be collected to the degree they are available,
but caution must be exercised in interpreta-
tion ofresults. For example, animal breeders
are likely to bias this end point by intention-
ally selecting for high fertility in males. Also,
in the case ofhumans some standard indices
ofmale fertility (e.g., number ofoffspring)
may be difficult to interpret because they are
heavily influenced by multiple factors (such as
lifestyle choices or use ofcontraceptives).
Thus it may be advantageous to consider
additional end points in humans, e.g., the
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time to conception for couples wishing to
have children.
HowDoPertubaions inthe
Homeostaic Balance C by
Endocrine Disruptors Lead to
UntowardEecs SuchAsImpaired
ReproductiveFunction?
The working group considered this question
from both qualitative and quantitative per-
spectives. From a qualitative perspective we
considered what biologic processes likely to
be affectedbyendocrine disruptors should be
considered in the development of models.
From a quantitative perspective we then con-
sidered what magnitude ofchange consti-
tutes an adverse effect or impaired function.
Both ofthese questions should be considered
because one might be able to detect quantita-
tive changes in many parameters that would
not necessarily constitute an adverse effect of
an endocrine disruptor.
Qualitatively, the processes that should be
incorporated into risk assessment models
include synthesis oftesticular hormones (both
steroid and peptide); clearance ofhormones;
biotransformation ofhormones to metabo-
lites with quantitatively different efficacy or
potency, or biologic activities qualitatively dif-
ferent than those ofthe parent compound; and
the disposition ofhormones, e.g., degree of
plasmaprotein binding, volumeofdistribution,
and sequestration in adipose tissue, bone, or
other repository sites. In addition, models
should incorporate basal levels ofhormone
receptors as well as their fractional occupancy
by endogenous hormones and endocrine dis-
ruptors and resultant changes in function. It is
important to emphasize that in some cases
hormone receptors may have activity in the
absence ofligand binding, and that receptors
may be activated by mechanisms other than
binding oftheir cognate hormones. For exam-
ple, steroidhormone receptors maybeactivated
by phosphorylation secondary to activation of
growthfactor-initiated kinase cascades (22).
In addition to considering levels of
receptors and their ligands, it is important to
consider the cellular context in which these
molecules produce their effects. For example,
the net cellular effect that results from the
binding ofa polypeptide hormone to a cell
surface receptor maydepend on the level ofG
proteins, enzymes involved in the formation
and breakdown ofsecond messengers, etc.
(23). The effects ofnuclear receptors may
depend upon the levels ofcoactivators, core-
pressors, and other proteins involved in
transcription control (24). The levels and
activities ofthese types offactors must also be
incorporated into quantitative models.
Finally, factors that affect either the rates
ofcell proliferation or cell death in the testes
must also be included. These could be agents
that act via mechanisms directly involving
receptors for hormones and autocrine or
paracrine factors as well as agents that act by
virtue oftheir chemical or physical properties
rather than receptor interactions. These latter
agents might include toxicants considered
historically under the rubric ofreproductive
toxicants but that have not previously been
thought ofas endocrine disruptors.
In terms ofdefining the magnitude of
change that constitutes endocrine disruption,
the working group essentially relied on the
basic concept ofhomeostasis. Ifone views
homeostasis as a process to maintain biologic
parameters within a normal range, then any
change that causes the value ofa parameter to
fall outside the normal set ofvalues can be
considered an adverse effect. In other words,
homeostatic mechanisms could not correct for
the biologic insult. This is also consistent with
the manner in which one considers the values
for any biologic parameter in an individual.
The physician or the veterinarian knows that
values for any parameter vary within the pop-
ulation, and thus he/she considers whether the
measured parameter falls within the normal
range. Thus the working group considers an
adverse effect to be any change in the parame-
ters ofa model (e.g., hormone levels, receptor
occupancy, steroid clearance) that falls outside
the normal range for the species being consid-
ered. In many cases the range ofnormal values
for parameters ofinterest and their periodic
variation have already been determined for
humans and manyanimal species.
HowCanTheseChangesBeQ!zantified?
Most parameters previously identified can be
quantitatively measured by existing chemical,
immunologic, or bioassay methods. This is
certainly true for the endogenous hormones
and receptors that play central roles in testicu-
lar function. It is important to reemphasize,
however, that this is not the case for many of
the endocrine-disrupting chemicals in the
environment and we recommend that efforts
be made to develop such technologies and to
make high purity chemicals available for both
analytic andbiologic studies.
Incorporating suchdata into aquantitative
model also requires knowledge ofthe binding
affinities ofthe xenobiotic agent to receptors
and carrier proteins. Furthermore, the parti-
tioningofthe agent between blood and tissues
and the kinetics ofmetabolic dearance ofthe
toxicant must be measured.
ByWhatMecbanismsDoEndocrine
Disruptors PturbEndocrine
HomeostasistoAlterTesticularFunction
andIncreaseRisksfromNonnalL^eels
ofEndogenousHormones?
At the cellular level, endocrine disruptors
may act directly on the testes or indirectly at
other sites to affect testicularfunction, and in
either case the molecular mechanism ofthese
effects may be due to interactions with hor-
mone receptors or at nonreceptor sites.
Within the testes the major receptors to be
considered are those for estrogens, andro-
gens, and thyroid hormones, and endocrine
disruptors could function as agonists or
antagonists at these receptor sites. Agents act-
ing at the level ofthe testes but by nonrecep-
tor mechanisms include those that alter
spermatogenesis, germ cell proliferation or
apoptosis, and autocrine or paracrine interac-
tions affecting tissue functions, meiosis, or
differentiation ofspermatids.
Receptor mechanisms at nontestes sites
would again include endocrine disruptors
with either agonist or antagonist activity at
estrogen, androgen, and thyroid receptor
sites. Models should put particular emphasis
on these receptors in the hypothalamus and
pituitary, which can affect the testes via alter-
ations in gonadotropin production and secre-
tion and by nuclear receptors in the liver that
can alter hormone clearance via enzyme
induction and endogenous hormone disposi-
tion via changes in the synthesis of serum-
binding proteins such as sex steroid-binding
globulin (25).
A variety ofnonreceptor mechanisms at
nontestes sites should also be included. These
include any hepatic effects that would alter
levels or activities of metabolic enzymes
using endogenous hormones as substrates;
any hypothalamic or pituitary effects that
alter gonadotropin or prolactin levels (e.g.,
hypothalamic effects of compounds with
dopaminergic activity that might alter
gonadotropin-releasing hormone produc-
tion), or mechanisms that perturb thyroid-
stimulating hormone and/or thyroid-releasing
hormone levels.
WhatOtherFacorsShouldBe
ConsideredintheDevelopmentof
ModelstoAssesstheE&s ofEndocrine
Disruptors onTesticularFunction?
There are an enormous number of addi-
tional factors that could be built into models
to assess low-dose effects of endocrine dis-
ruptors on testicular function or other bio-
logic end points, and these could not be
discussed in depth during a 2-day meeting.
The working group thus decided to list fac-
tors likely to be of major importance. The
major areas to be considered are age, disease,
genetic variability, and lifestyle factors.
There is substantial literature on many of
these factors which would serve to provide
specifics for incorporation into models.
There is substantial literature on
the effects of age on testicular function
in humans and animals. This literature
includes information on the three general
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end points, sperm production, sperm char-
acteristics, and steroidogenesis, that would
be the focus of an integrated model to
describe testicular functioning in response to
endocrine disruptors.
Alarge number ofdiseases affect testicular
function either directly or indirectly.
However, many of these are not necessarily
related to environmental exposures to
endocrine disruptors. There is a strong inter-
est in the possible relationship(s) between
endocrine disruptors and the increasing inci-
dence oftesticular cancer. Theworkinggroup
felt that this specific disease should be
explicitlyconsidered.
Experimental studies can be performed
with inbred strains ofanimals to minimize the
effects ofgenetic background, but genetic dif-
ferences must be included in models designed
to predict human health effects. Certainly eth-
nicity should be included in baseline models,
as should genetic variations likely to have
major effects on the levels ofendocrine dis-
ruptors and/or endogenous hormones (e.g.,
bioactivation or clearance) or their effects
(receptor subtypes). The recently announced
National Institute ofEnvironmental Health
Sciences Environmental Genome Project can
be expected to provide useful information
about genetic loci ofspecial importance for
quantitative modeling purposes.
A variety oflifestyle factors are also of
prime importance to a biologic end point
such as testicular function, and the literature
contains specific information on each ofthese
that could be used for development ofmod-
els. Specific factors include diet and nutri-
tional status; lifestyle factors such as stress and
exercise; geographic location (as temperature
and photoperiods can affect testicular
function); therapeutic and recreational drug
use; andsmoking anddrinkingpatterns.
Summary
The use of an integrated biologic read-out
such as testicular function is particularly well
suited to develop models that can be used to
quantitatively assess the effects ofendocrine
disruptors in adult organisms. This approach
is initially more complex than those that focus
on more discrete end points such as a single
type ofreceptor-mediated response (e.g., the
activation ofan individual gene or reporter by
an environmental estrogen or androgen).
Although the latter can be very valuable for
many purposes (e.g., high throughput screen-
ing), the use ofintegrated system end points
enables one to model effects at the level ofthe
whole organism. More specifically, an inte-
grated approach a) can incorporate homeosta-
tic mechanisms that cannot be quantitatively
incorporated into more discrete end points
measured in a single cell type or organ; b) can
describe cases in which a single endocrine dis-
ruptor may have effects at multiple sites, and
possibly via different mechanisms, and thus
assess the overall impact of the chemical on
function at the organismal level; and c) can
develop models that quantitatively describe
situations in which endocrine disruptors and
reproductive toxicants acting by other mecha-
nisms are both present, since this ultimately
represents the real-world scenario.
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